New Delhi, Aug. 19 -- Shares of Moderna climbed nearly 100% in pre-market trading on Wednesday after its mRNA vaccine combined with Merck's immunotherapy Keytruda succeeded in a late-stage trial for skin cancer.

The study is ongoing, but interim results found the treatment, Intismeran, met both its primary target of reducing cancer recurrence and its secondary goal of keeping cancers from spreading to other parts of the body.

Published by HT Digital Content Services with permission from MINT....